TCN2 Antibody - #DF12767

Figure 5 Phenotypes and pathological changes of TCN2 K77M mice and their diabetic models (A) Representative images of immunofluorescence staining of TCN2 in WT and TCN2 K77M mice at indicated magnifications. TCN2 is abundantly aggregated in tubular cells of TCN2 K77M mice, forming plaques. Scale bars: 400, 40, and 10 μm. (B and C) (B) Body weight (g) and (C) blood glucose (mM) in WT (n = 5), TCN2 K77M (n = 6), WT diabetic (n = 13), and TCN2 K77M diabetic (n = 13) mice. (D and E) (D) Serum creatinine and (E) UACR (mg/mg) levels in WT (n = 5), TCN2 K77M (n = 6), WT diabetic (n = 13), and TCN2 K77M diabetic mice (n = 13) after 24 weeks post STZ injection. ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, according to two paired samples with a Wilcoxon test. Data are represented as mean ± SEM. (F) Representative images of PAS staining and immunohistochemical staining against α-SMA and F4/80 of kidney images from WT, TCN2 K77M, WT diabetic, and TCN2 K77M diabetic mice. Scale bars: 40 and 100 μm. (G–I) (G) Quantification of the tubular injury score in WT (n = 5), TCN2 K77M (n = 6), WT diabetic (n = 13), and TCN2 K77M diabetic (n = 13) mice. Quantification of the positive area of α-SMA (H) and F4/80 (I) in WT (n = 4), TCN2 K77M (n = 4), WT diabetic (n = 4), and TCN2 K77M diabetic (n = 4) mice. ∗p < 0.05, ∗∗p < 0.01, according to two paired samples with a Wilcoxon test. Data are represented as mean ± SEM. (J) Transmission electron microscopy of WT, TCN2 K77M, WT diabetic, and TCN2 K77M diabetic mice; 10 randomly selected fields from each group were counted, and the structural abnormalities of mitochondria in renal tubular cells are indicated by arrows. ∗∗∗∗p < 0.0001, according to two paired samples with a Wilcoxon test. Data are represented as barplots showing mean and SEM. UACR, urine albumin-to-creatinine ratio; PAS, periodic acid-Schiff. Scale bars: 1 and 2 μm.